GSK1292263, with the CAS number 1032823-75-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications. It is classified as a selective inhibitor of certain enzymes, particularly those involved in the modulation of inflammatory pathways. This compound has shown promise in preclinical studies for its ability to reduce inflammation and may have implications in treating various autoimmune and inflammatory diseases. GSK1292263 is characterized by its specific molecular structure, which allows it to interact selectively with target proteins, thereby influencing biological processes. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety in clinical settings. As with many investigational compounds, ongoing research is essential to fully elucidate its mechanism of action, therapeutic potential, and any associated side effects. Overall, GSK1292263 represents a significant area of interest in drug development, particularly in the context of inflammatory disorders.

GSK1292263

1032823-75-8: GSK1292263, with the CAS number 1032823-75-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications. It is classified as a selective inhibitor of certain enzymes, particularly those involved in the modulation of inflammatory pathways. This compound has shown promise in preclinical studies for its ability to reduce inflammation and may have implications in treating various autoimmune and inflammatory diseases. GSK1292263 is characterized by its specific molecular structure, which allows it to interact selectively with target proteins, thereby influencing biological processes. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for determining its efficacy and safety in clinical settings. As with many investigational compounds, ongoing research is essential to fully elucidate its mechanism of action, therapeutic potential, and any associated side effects. Overall, GSK1292263 represents a significant area of interest in drug development, particularly in the context of inflammatory disorders.

GSK1292263 is a GPR119 agonist and has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

CAS 1032823-75-8

GSK1292263

GSK1292263

Ref: 54-BUP10033

GSK1292263

Ref: TM-T2701